SRRK

Scholar Rock Holding Corp

Add to Watchlist

Advanced Chart

34.615

-2.365(-6.395%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

35.770

Open

31.990

VWAP

34.21

Vol

5.33M

Mkt Cap

3.29B

Low

30.000

Amount

182.50M

EV/EBITDA(TTM)

Total Shares

79.75M

3.20B

EV/OCF(TTM)

P/S(TTM)

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

9 Analyst Rating

46.93% Upside

Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50.86 USD with a low forecast of 46.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

46.93% Upside

Current: 34.615

Low

46.00

Averages

50.86

High

57.00

46.93% Upside

Current: 34.615

Low

46.00

Averages

50.86

High

57.00

Raymond James

NULL

Strong Buy

upgrade

$49 -> $53

2025-07-29

Reason

Raymond James

Price Target

$49 -> $53

2025-07-29

upgrade

NULL

Strong Buy

Reason

Raymond James assumed coverage of Scholar Rock with a Strong Buy rating with a price target of $53, up from $49. Scholar Rock's apitegromab, a mAb targeting latent myostatin, is progressing towards a September 22 PDUFA date in spinal muscular atrophy, and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner, the analyst tells investors in a research note. Beyond SMA, Scholar Rock's myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential outlicensing and partnerships in the obesity space can offer another source of near-term optionality, Raymond James argues.

Cantor Fitzgerald

initiated

2025-07-17

Reason

Cantor Fitzgerald

Price Target

2025-07-17

initiated

Reason

Cantor Fitzgerald initiated coverage of Scholar Rock with an Overweight rating.

JPMorgan

Overweight

maintain

$46

2025-06-26

Reason

JPMorgan

Price Target

$46

2025-06-26

maintain

Overweight

Reason

JPMorgan added Scholar Rock to the firm's Analyst Focus List as a growth idea and also placed the stock on "Positive Catalyst Watch." JPMorgan remains focused on the potential for apitegromab in spinal muscular atrophy and the company's execution on regulatory approvals and launches for the drug across key geographies, starting with the U.S. If approved, which is "highly likely" given the positive results from the Phase 3 SAPPHIRE trial in patients with non-ambulatory Type 2/3 spinal muscular atrophy, JPMorgan sees potential for "robust launches," the analyst tells investors in a research note. The firm keeps an Overweight rating on Scholar Rock with a $46 price target.

HC Wainwright & Co.

Andres Maldonado

Strong Buy

Maintains

$40 → $50

2024-11-26

Reason

HC Wainwright & Co.

Andres Maldonado

Price Target

$40 → $50

2024-11-26

Maintains

Strong Buy

Reason

Truist Securities

Srikripa Devarakonda

Strong Buy

Maintains

$36 → $45

2024-11-25

Reason

Truist Securities

Srikripa Devarakonda

Price Target

$36 → $45

2024-11-25

Maintains

Strong Buy

Reason

Truist raised the firm's price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares after Biohaven's Phase 3 study spinal muscular atrophy failed to meet the primary endpoint. Truist now sees a stronger case for Scholar Rock in SMA and are increased its peak sales to $1.5B from $1.2B. The SMA market opportunity could be larger than anticipated given the removal of this competitive overhang, the analyst tells investors in a research note. With positive SMA data and apitegromab in a Phase 2 trial for obesity, the firm now sees Scholar Rock as a potential takeout target.

Wedbush

David Nierengarten

Buy

Maintains

$40 → $47

2024-11-25

Reason

Wedbush

David Nierengarten

Price Target

$40 → $47

2024-11-25

Maintains

Buy

Reason

Wedbush raised the firm's price target on Scholar Rock (SRRK) to $47 from $40 and keeps an Outperform rating on the shares. Biohaven's (BHVN) trial miss leaves Scholar Rock's apitegromab as the only agent in the class likely to gain approval in the near-term in spinal muscular atrophy, the analyst tells investors in a research note. The firm now anticipates greater market penetration with Scholar Rock's treatment with a launch possible as early as Q4 of 2025.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Scholar Rock Holding Corp (SRRK.O) is -14.08, compared to its 5-year average forward P/E of -7.77. For a more detailed relative valuation and DCF analysis to assess Scholar Rock Holding Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.77

Current PE

-14.08

Overvalued PE

-3.07

Undervalued PE

-12.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.87

Current EV/EBITDA

-11.77

Overvalued EV/EBITDA

1.61

Undervalued EV/EBITDA

-7.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.87

Current PS

205.63

Overvalued PS

72.84

Undervalued PS

-17.09